MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » 7 medtech stories we missed: Feb. 17, 2017

7 medtech stories we missed: Feb. 17, 2017

By

[Image from unsplash.com]
Several companies released diabetes study results this week, while companies like BioTime closed on their public offerings and Pixium implanted its first bionic eye. Here are 7 medtech stories we missed this week, but were still worth mentioning.

1. Insulet touts glucose control study

Insulet Corp. announced the results from its first feasibility study of its Omnipod Horizon hybrid closed-loop system in a Feb. 17 news release. The positive results showed that the glucose control algorithm performed well and was safe to used day and night for adults who have type 1 diabetes. It also showed that it was effective at night with minimal hypoglycemia and fasting glucose. The Insulet study had 24 participants with type 1 diabetes and took place over a 36 hour period. The participants used a modified version of the Omnipod, a Dexcom continuous glucose sensor, and a model predictive control algorithm created by Insulet.

2. Pixium announces first Spanish implantation of Iris II ‘bionic eye’

The Institute of Ocular Microsurgery in Barcelona, Spain implanted the bionic vision system Iris II in the first Spanish patient, according to a Feb. 16 news release. The vision system has a bio-inspired camera and a 150-electrode epiretinal implant that can be removed if needed. Pixium Vision developed the bionic vision system to help patients who have lost their eyesight, and the Iris II is designed to help patients who lost their eyesight from retinitis pigmentosa. The surgery was performed by Dr. Borja Corcostegui, founder and medical director of the Institute of Ocular Microsurgery and a vitreoretinal surgeon.

3. Valeritas releases data for V-Go wearable insulin delivery device

Valeritas Holdings recently touted in a Feb. 16 news release that its V-Go Wearable Insulin Delivery device proved to have a greater reduction in A1c and insulin dose in patients who have type 2 diabetes. The study analyzed the electronic medical records from a multicenter diabetes system in the U.S. It evaluated the data of 107 patients to determine that patients had fewer insulin doses and needle sticks while using the V-Go, compared to using insulin pens.

4. Polyganics’ Stop Neuroma study shows reduction in pain

Polyganics announced in a Feb. 16 news release that its Stop Neuroma study has shown a sharp improvement in pain reduction in patients who participated in the program. The Stop Neuroma (surgical treatment of symptomatic neuroma) program was designed to determine how well the Polyganics Neurocap worked for reducing painful neuroma formation. The Neurocap is a nerve capping device that is the only approved dedicated device for managing symptomatic neuromas surgically. Patients saw an average pain reduction of 84% after a 3 month use, and patients who used it for 12 months felt they had improvement in daily functioning and quality of life.

5. BioTime closes public offering

BioTime has closed its underwritten public offering, according to a Feb. 15 news release. It sold 7,453,704 shares of its common stock at an offering of $2.70 per share. The company raked in approximately $20.1 million before the deduction of underwriting discounts, commissions and other expenses. BioTime will use the proceeds from the offering to fund clinical trials, research and development activities, general working capital and general corporate purposes.

6. Tandem Diabetes Care: Data shows its sensor-augmented pump has advantages over Medtronic

Tandem Diabetes Care recently did a study that compared data from its sensor-augmented pumps (SAPs) to Medtronic’s Minimed. According to a Feb. 15 news release, the Tandem SAP had significant clinical advantages like a reduction in hypoglycemia, increased time in range and an improved glycemic control. The data showed that about half of Medtronic SAP users were actively using a feature that suspended insulin delivery when blood glucose levels fell below a certain threshold. Both sets of data from Tandem and Medtronic used patients with type 1 and type 2 diabetes who used a SAP for at least 6 months and used a continuous glucose monitor for more than 15 days during the first 6 months.

7. FDA green-lights FlowAid Medical’s FA100 SCCD circulation aid

FlowAid Medical received FDA clearance this week for its FA100 SCCD (sequential continuous contraction device), according to a Feb. 15 news release. The FA100 SCCD is a handheld 4-channel electrical muscle stimulator that is small, lightweight and portable and provides low-frequency stimulation in sequential patterns. it requires no external pressure to the legs and allows the patient to move freely without interfering with daily activities. It is used on patients who have an increase of local blood circulation, immediate post-surgical stimulation of calf muscles to prevent venous thrombosis, and for the prevention or stopping of disuse atrophy and edema reduction. The FA100 SCCS also received CE Mark approval in July 2016 and Health Canada approval in August 2016.

Here’s what we missed last week.

 

In case you missed it

RSS From Medical Design & Outsourcing

  • HHS could make permanent pandemic-related exemptions for some devices
    HHS has used the Trump administration’s waning days to propose permanently exempting certain medical devices — including infusion pump controllers and fetal monitors — from the FDA 510(k) clearance process. In a notice published Jan. 15, 2021, in the Federal Register, the agency also listed seven types of patient examination gloves that it has decided… […]
  • Medtechs can’t set digital strategies aside – DTW Podcast
    Digital connectivity no longer belongs in the final slides of a medtech company’s pitch deck. In the latest DeviceTalks Weekly podcast, three leaders pushing for connected medical devices explain the need to incorporate data collection and monitoring functionality in new devices: Scott Huennekens, who advanced the “digital surgery” strategy when he helped launch Verb Surgical,… […]
  • Protolabs to acquire 3D Hubs for up to $330M
    Protolabs (NYSE: PRLB) today announced it plans to acquire Amsterdam-based 3D Hubs, an online manufacturing platform that provides engineers with on-demand access to a global network of approximately 240 manufacturing partners. The transaction creates a comprehensive digital manufacturing offer for custom parts, expanding Protolabs’ breadth of capabilities as well as adding a broader offering of pricing and… […]
  • These medtech stocks performed the best in 2020
    While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward. Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while… […]
  • Covestro tests plastics against high-strength hospital disinfectants
    Covestro announced that it recently teamed with disinfectant manufacturer Metrex to test six different Covestro polycarbonate materials against three of Metrex’s products, which are widely used throughout the healthcare industry. As is customary for rapidly assessing the compatibility of plastics to disinfectants, test specimens were pre-strained and underwent several wipe-and-dry cycles with Metrex disinfectants to… […]
  • Integer expands N.Y. battery plant
    Integer announced today that it recently broke ground on an expansion of its Alden, N.Y., facility to accommodate new equipment that will substantially increase the plant’s production capacity for rechargeable Xcellion lithium-ion batteries. The project kicked off in mid-December 2020 and will add both production equipment and a build-out of Integer’s existing facility. The company… […]
  • Diversified Plastics adds high-efficiency vertical presses
    Diversified Plastics (DPI) announced that it recently installed six all-electric vertical injection molding presses. These presses will join DPI’s existing assemblage of vertical presses and provide increased production capacity to meet growing demand from medical device and other original equipment manufacturers (OEMs). DPI uses vertical presses for over-molding and insert-molding, capabilities often required for medical… […]
  • Traco Power expands power supply line for portable medical equipment
    Traco Power announced that it has expanded its TPP 450 high-density 3×5 power supply series. The series now offers Protection Class II models (TPP 450BA-M Open-Frame Models and TPP 450B-M Enclosed with Fan Models), designed for non-stationary requirements where connection to ground is not possible. Key approvals on the original series remain on the expanded… […]
  • Reflow Medical launches low-profile reinforced support catheters
    Reflow Medical today announced it has launched its Reflow Spex Low Profile reinforced support catheters. The Spex LP catheters are designed to provide the lowest profile tip to access and cross the tightest and most complex lesions with a supportive system. They come in 0.014 in. and 0.018 in. sizes and can be combined with… […]
  • Former CDER head Woodcock to lead FDA for now
    FDA veteran Dr. Janet Woodcock has been tapped as interim FDA commissioner by the Biden administration, according to published reports. An article by BioCentury also said that former FDA commissioner David Kessler, who had been mentioned as a possible replacement for current commissioner Stephen Hahn, will be a consultant to the agency but will not… […]
  • What’s next for the FDA and for Stephen Hahn?
    Outgoing FDA commissioner Stephen Hahn says he needs some time to reflect on his future after leading the FDA for a little over a year. It’s hard to blame him. Hahn’s brief tenure at FDA has been rocky, to say the least. (News of his temporary replacement broke on Thursday, when the incoming Biden administration… […]